Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

Summary

It is evidenced that efgartigimod can rapidly and significantly improve the symptoms of myasthenia gravis. The global multicenter clinical trials hace confirmed that efgartigimod is safe and well tolerated. Few case reports showed that perioperative efgartigimod combined with thymectomy was safe and feasible. However, there was no sufficient data on safety and efficacy of this regimen in the treatment for patients with myasthenia gravis and thymomas. Therefore, this trial aims to evaluate the efficacy and safety of perioperative efgartigimod and thymectomy for patients with myasthenia gravis and thymomas.

Timeline

Start

2024-02-01

Primary completion

2026-12-30

Completion

2027-06-30

Publications

• Wang S, Zhu M, Dong J, Zhang Y, Luo S, Jiang J, Cheng Z, Li Z, Yang W, Yu Y, Liu Z, Fan J, Xu X, Liu P, Zhang Z, Can F, Liang F, Jiang X, Tan L, Ding J. Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial. J Thorac Oncol. 2025 Aug;20(8):1120-1130. doi: 10.1016/j.jtho.2025.04.014. Epub 2025 May 2.

Drugs

Indications